The global companion diagnostic tests in oncology market is projected to skyrocket, reaching US$ 17.0 billion by 2034. This growth is fueled by the increasing use of these tests in personalized cancer therapies, with advancements in genomic profiling, liquid biopsies, and AI further propelling the market forward.